ibandronic acid has been researched along with Age-Related Osteoporosis in 155 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.29) | 18.2507 |
| 2000's | 67 (43.23) | 29.6817 |
| 2010's | 64 (41.29) | 24.3611 |
| 2020's | 22 (14.19) | 2.80 |
| Authors | Studies |
|---|---|
| Ishimoto, T; Matsumoto, Y; Nakano, T; Ozasa, R; Saito, M | 1 |
| Ishimoto, T; Matsugaki, A; Matsumoto, Y; Nakano, T; Ozasa, R; Saito, M | 1 |
| Dong, S; Hu, Y; Ke, Z; Lv, M; Shen, J; Song, L; Wu, K; Xu, K; Yuan, Y | 1 |
| Chang, YF; Hsu, JC; Hsu, YH; Li, CC; Liang, FW; Ou, HT; Peng, ZY; Wu, CH | 1 |
| Kaseda, R; Mitsuboshi, S; Narita, I | 1 |
| Kotake, K; Mitsuboshi, S | 1 |
| Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M | 1 |
| Chen, CH; Chen, WJ; Chen, YM; Chien, LN; Ku, CK; Li, CY; Lin, SY | 1 |
| Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| McConnell, M; Shieh, A | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 2 |
| Chan, DC; Chang, YF; Chen, HM; Fu, SH; Hsu, CC; Hwang, JS; Lin, JW; Wang, CY; Wu, CH; Yang, RS; Yang, TH | 1 |
| Chen, Y; Huang, Y; Xiao, Y | 1 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O | 1 |
| Akagawa, M; Imai, Y; Kasukawa, Y; Kawatani, M; Miyakoshi, N; Nagahata, I; Nagasawa, H; Ono, Y; Sato, C; Shimada, Y; Tsuchie, H; Yuasa, Y | 1 |
| Eastell, R; Fontalis, A | 1 |
| Goetz, V; Homik, J; Kendler, D; Koller, G; McAlister, FA; Vandermeer, B; Ye, C | 1 |
| Chiba, K; Enomoto, H; Era, M; Isobe, Y; Ito, M; Miyazaki, S; Morimoto, S; Nakashima, S; Okazaki, N; Osaki, M; Ota, S; Sato, S; Tashiro, S; Tomita, M; Tsukazaki, T; Watanabe, T; Yabe, Y; Yamada, S; Yoda, I; Yokota, K; Yonekura, A | 1 |
| Baek, IH; Ha, JY; Kim, KW; Lee, JS; Park, HY; Park, SB | 1 |
| Betsch, M; Colarossi, G; Eschweiler, J; Maffulli, N; Migliorini, F; Tingart, M | 1 |
| Asao, Y; Endo, K; Hagino, H; Hashimoto, J; Ito, M; Katsumata, K; Matsumoto, R; Mizunuma, H; Nakamura, T; Nakano, T; Yamamoto, M | 1 |
| Ikegami, S; Kamimura, M; Kato, H; Nakamura, Y; Suzuki, T; Uchiyama, S | 1 |
| Yalla, N | 1 |
| Hagino, H; Ikeda, S; Imanishi, Y; Miyakoshi, N; Nakajo, S; Sakai, A; Tsurukami, H | 1 |
| Guo, Y; Song, X; Zhao, H | 1 |
| Hagino, H; Hashimoto, J; Ito, M; Mizunuma, H; Nakamura, T; Nakano, T; Tobinai, M | 1 |
| Adami, S; Gatti, D; Kunnathully, V; Orsolini, G; Rossini, M | 1 |
| Adamidou, F; Anagnostis, P; Charizopoulou, M; Garipidou, V; Goulis, DG; Karagiannis, A; Karras, S; Vakalopoulou, S; Vyzantiadis, TA | 1 |
| Goossens, N; Rubbia-Brandt, L; Spahr, L | 1 |
| Benhamou, CL; Binkley, N; Bolognese, MA; Bone, HG; Bonnick, SL; Czerwinski, E; Ferreira, I; Ghelani, P; Hall, JW; Moffett, A; Palacios, S; Recknor, C; Siddhanti, S; Wagman, RB | 1 |
| Gamsjaeger, S; Klaushofer, K; Misof, BM; Muschitz, C; Paschalis, EP; Patsch, JM; Pietschmann, P; Prokop, E; Resch, H; Roschger, P | 1 |
| Grajek, S; Mączyński, M; Mularek-Kubzdela, T | 1 |
| Średniawa, B | 1 |
| Capaldo, A; Di Somma, C; Gimigliano, F; Iolascon, G; Menditto, E; Orlando, V | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Ogrin, C | 1 |
| Alihanoglu, YI; Eryilmaz, U; Evrengul, H; Kilic, ID; Uludag, B | 1 |
| Agodoa, I; Kruse, M; Orwoll, E; Parthan, A; Silverman, S | 1 |
| Chung, CK; Kang, YK; Park, SB; Park, SH | 1 |
| Ohashi, S; Ono, K; Tanaka, S | 1 |
| Al-Rifaiy, MQ; Almas, K; Javed, F; Vohra, F | 1 |
| Shiraishi, A | 1 |
| Alay, S; Güzelküçük, U; Kesikburun, S; Tan, AK; Yavuz, F | 1 |
| Hashimoto, J; Iida, S; Kawanishi, T; Nakai, K; Tobinai, M | 1 |
| Reid, IR | 1 |
| Modi, A; Sajjan, S; Siris, ES; Steve Fan, CP | 1 |
| Amrein, K; Kaider, A; Kocijan, R; Misof, BM; Muschitz, C; Pahr, D; Patsch, JM; Pietschmann, P; Resch, H | 1 |
| Asao, Y; Hagino, H; Hashimoto, J; Inoue, T; Ito, M; Katsumata, K; Mizunuma, H; Nakamura, T; Nakano, T; Shinomiya, K | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Ding, H; Gu, K; Hou, Y; Liu, C; Tuoheti, Y; Xu, C | 1 |
| Hashimoto, J; Nakamura, T; Nakano, T; Tobinai, M; Yamamoto, M; Yoshida, S | 1 |
| Jäger, M; Krauspe, R; Rump, LC; Schmitz, M; Tillmann, FP | 1 |
| Hashimoto, J; Ito, M; Nakamura, T; Tobinai, M; Yoshida, S | 1 |
| Ataoğlu, B; Berkay, AF; Eren, TK; Kaptan, AY; Yapar, AE | 1 |
| Keating, GM | 1 |
| Hu, H; Huang, K; Li, Y; Liu, X; Ma, Z; Xu, X; Zhou, M | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Li, N; Liao, Y; Sun, G; Wu, Q; Xie, H; Zeng, Y; Zhou, G; Zhou, J | 1 |
| Kutilek, S; Langer, J; Plasilova, I | 1 |
| Kõks, S; Laius, O; Maasalu, K; Märtson, A | 1 |
| Hagino, H; Hashimoto, J; Katagiri, H; Okano, T | 1 |
| Bauss, F; Bergström, B | 1 |
| Hochberg, MC | 1 |
| Bartl, R | 1 |
| Emkey, RD; Kohles, JD; Sambrook, PN; Sebba, AI | 1 |
| Okazaki, R | 1 |
| Barr, CE; Blumentals, WA; Harley, C; Harris, ST; Poston, SA; Reginster, JY; Silverman, SL | 1 |
| Blumentals, WA; Cole, RE; Harris, ST; Huang, L; Silverman, SL | 1 |
| Masuda, H; Tanaka, S | 1 |
| Gold, DT; Safi, W; Trinh, H | 1 |
| Epstein, S; Jeglitsch, M; McCloskey, E | 1 |
| Bunyaratavej, N; Kittimanon, N; Kitumnuoypong, T; Lektrakoon, S; Pauvilai, P; Wajanavisit, W | 1 |
| Bruyère, O; Hiligsmann, M; Neuprez, A; Reginster, JY | 1 |
| Binkley, NC; Dasic, G; Fries, MA; Gruntmanis, U; Lewiecki, EM; Orwoll, ES | 1 |
| Dobbins, EK; Duvall, CA; Gates, BJ; Sonnett, TE | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Lindor, KD; Petz, JL; Silveira, MG; Treeprasertsuk, S | 1 |
| Aapro, MS | 1 |
| Griffith, JF; Hung, VY; Kwok, AW; Lee, KK; Lee, VW; Leung, PC; Li, EK; Li, M; Qin, L; Tam, LS; Wong, KC; Zhu, TY | 1 |
| Linhartova, K; Sterbakova, G; Vyskocil, V | 1 |
| Tobinai, M | 1 |
| Adler, G; Herdt, K; Klaus, J; Reinshagen, M; von Boyen, GB; von Tirpitz, C | 1 |
| Fries, M; Fuerst, T; Genant, HK; Lewiecki, EM | 1 |
| Abarca, J; Campbell, HE; Martin, KE; White, TJ; Yu, J | 1 |
| Dong, HN; Kang, JF; Kang, ZK; Li, YW; Liu, DG; Xue, XM; Zhang, J; Zhang, KJ | 1 |
| Sewerynek, E; Stuss, M | 1 |
| Bjelakovic, G; Giljaca, V; Gluud, C; Krstic, MN; Rudic, JS | 1 |
| Amrein, K; Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A; Kniepeiss, D; Kornprat, P; Pieber, T; Tscheliessnigg, KH; Wagner, D | 1 |
| Curtis, JR; Delzell, E; Matthews, R; Saag, KG; Yun, H | 1 |
| Leal, S; Ziltener, JL | 1 |
| Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W | 1 |
| Lo, JC; O'Ryan, FS | 1 |
| Hommann, M; Kaemmerer, D; Lehmann, G; Schmidt, B; Settmacher, U; Wolf, G | 1 |
| Hakala, M; Hannonen, P; Heikkinen, J; Hienonen-Kempas, T; Kröger, H; Lehtonen-Veromaa, M; Paimela, L; Tuomiranta, T; Valleala, H | 1 |
| Åsberg, A; Bollerslev, J; Dolgos, S; Godang, K; Hartmann, A; Midtvedt, K; Olsen, IC; Pfeffer, P; Reisæter, AV; Sagedal, S; Smerud, KT; Ueland, T | 1 |
| Airia, P; Borisova, N; Ferko, NC; Grima, DT; Thompson, MF | 1 |
| Biskobing, DM; Downs, R; Novy, AM | 1 |
| Abendroth, K; Hein, G; Hommann, M; Kornberg, A; Lehmann, G; Patzer, N; Scheele, J; Seifert, S; Voigt, R | 1 |
| Chapurlat, RD; Delmas, PD | 1 |
| Adler, G; Boehm, BO; Hofbauer, LC; Klaus, J; Kratzer, W; Mason, R; Reinshagen, M; Steinkamp, M; von Tirpitz, C | 1 |
| Dorst, A; Faber, H; Ibach, K; Preuss, J; Ringe, JD | 1 |
| Dorst, A; Faber, H; Ibach, K; Ringe, JD; Sorenson, F | 1 |
| Burckhardt, P; Burnand, J; Fatio, S; Lamy, O; Pache, I; Sandini, L | 1 |
| Adami, S; Viapiana, O | 1 |
| Adami, S; Christiansen, C; Coutant, K; Delmas, PD; Felsenberg, D; Lorenc, RS; Mahoney, P; Robinson, J; Schimmer, RC | 1 |
| Chesnut, CH; Christiansen, C; Delmas, PD; Ettinger, M; Hoiseth, A; Mahoney, P; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA | 1 |
| Bauss, F; Russell, RG | 1 |
| Barrett, J; Bauss, F; Epstein, S; Worth, E | 1 |
| Bauss, F; Hannan, M; Müller, R; Smith, SY | 1 |
| Heidenreich, A; Ohlmann, CH | 1 |
| Hosking, DJ; Pande, I | 1 |
| Wallace, DJ | 1 |
| Baylink, DJ; Chesnut, CH; Emkey, R; Ettinger, MP; Harris, ST; Miller, PD; Recker, RR; Schimmer, RC; Wasnich, RD; Watts, NB | 1 |
| Kuehn, BM | 1 |
| Bauss, F; Eberhardt, C; Kurth, AH; Müller, S; Schwarz, M; Steinacker, M | 1 |
| McClung, M | 1 |
| Epstein, S; Zaidi, M | 1 |
| Jack, D | 1 |
| Dorst, A; Faber, H; Ringe, JD | 1 |
| Geusens, P; Reid, D | 1 |
| Dando, TM; Noble, S | 1 |
| Cooper, C | 1 |
| Epstein, S | 1 |
| Russell, RG | 1 |
| Guay, DR | 1 |
| Burke, MS; Simonelli, C | 1 |
| Fassbender, WJ; Stumpf, UC | 1 |
| Bauss, F; Dempster, DW | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Croom, KF; Scott, LJ | 1 |
| Açil, Y; Barkmann, R; Bauss, F; Delling, G; Glüer, CC; Hassenpflug, J; Helfenstein, A; Scholz-Ahrens, KE; Schrezenmeir, J; Stampa, B; Timm, W | 1 |
| Hashimoto, J | 1 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Curtis, JR; Saag, KG | 1 |
| Babić-Naglic, D; Grazio, S | 1 |
| Sambrook, P | 1 |
| Chesnut, CH; Epstein, S; Harris, ST; Kohles, JD; Zaidi, M | 1 |
| Hashimoto, J; Oshima, H; Tanaka, I | 1 |
| Bergman, G; Gaugris, S; Jansen, JP; Sen, SS | 1 |
| Klaus, J; König, HH; Konnopka, A; Kreck, S; Leidl, R; Matschinger, H; von Tirpitz, C | 1 |
| Babbitt, AM; Bone, HG; Lewiecki, EM; Ozturk, ZE; Piziak, VK | 1 |
| Bauss, F; Friedler, RM; Malluche, HH; Monier-Faugere, MC | 1 |
| Faus, SA; Price, PA; Williamson, MK | 1 |
| Cybulla, M; Grotz, W; Kirste, G; Nagel, C; Olschewski, M; Petersen, KG; Poeschel, D; Reichelt, A; Rump, LC; Strey, C; Uhl, M | 1 |
| Christgau, S; Christiansen, C; Cloos, PA; Lehmann, HJ; Mouritzen, U | 1 |
| Bauss, F; Hothorn, LH; Wagner, M | 1 |
56 review(s) available for ibandronic acid and Age-Related Osteoporosis
| Article | Year |
|---|---|
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2022 |
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zoledronic Acid | 2022 |
Risks of serious adverse events and kidney injury in patients treated with ibandronate: A systematic review and meta-analysis.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; Kidney; Osteoporosis | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal | 2020 |
Persistence and adherence to parenteral osteoporosis therapies: a systematic review.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis; Teriparatide | 2020 |
Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis.
Topics: Alendronate; Bayes Theorem; Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Pharmaceutical Preparations | 2021 |
Osteoporosis treatment: why ibandronic acid?
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis; Osteoporotic Fractures | 2013 |
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide | 2014 |
Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Implants; Dental Restoration Failure; Diphosphonates; Female; Ibandronic Acid; Imidazoles; Osseointegration; Osteoporosis; Ovariectomy; Surface Properties; Zoledronic Acid | 2014 |
[Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Durapatite; Haplorhini; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Rats; Spinal Fractures | 2014 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis | 2015 |
Ibandronate: A Review in Japanese Patients with Osteoporosis.
Topics: Administration, Intravenous; Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Japan; Lumbar Vertebrae; Osteoporosis; Risedronic Acid; Spinal Fractures | 2016 |
Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Regression Analysis; Treatment Outcome | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Pain | 2008 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis | 2009 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
[Drugs under development for osteoporosis ].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cathepsin K; Cathepsins; Denosumab; Diphosphonates; Drug Design; Humans; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes | 2009 |
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Humans; Ibandronic Acid; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid | 2009 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceutical; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Male; Osteonecrosis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2009 |
Challenges in clinical patient management.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis; Risedronic Acid; Tamoxifen | 2010 |
[Ibandronate].
Topics: Administration, Oral; Bone Density Conservation Agents; Clinical Trials, Phase II as Topic; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis; Randomized Controlled Trials as Topic; Spinal Fractures | 2011 |
[The role of i.v. ibandronate administration in osteoporosis therapy].
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Male; Osteoporosis; Randomized Controlled Trials as Topic; Sex Factors; Time Factors | 2011 |
Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Liver Cirrhosis, Biliary; Male; Osteoporosis; Randomized Controlled Trials as Topic | 2011 |
[Pelvic pain in the athlete: not always that simple...].
Topics: Athletes; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Pelvic Pain; Pubic Bone; Running; Sports; Withholding Treatment | 2012 |
Novel therapeutic options for osteoporosis.
Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid | 2002 |
Ibandronate: new options in the treatment of osteoporosis.
Topics: Administration, Oral; Diphosphonates; Disease Management; Female; Humans; Ibandronic Acid; Injections, Intravenous; Male; Osteoporosis | 2003 |
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
Topics: Animals; Bone Density; Bone Resorption; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Models, Animal; Osteoporosis | 2004 |
Ibandronate: a clinical pharmacological and pharmacokinetic update.
Topics: Biological Availability; Biotransformation; Diphosphonates; Dose-Response Relationship, Drug; Humans; Ibandronic Acid; Injections, Intravenous; Intestinal Absorption; Osteoporosis; Tissue Distribution | 2004 |
Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Neoplasms; Osteoporosis; Product Surveillance, Postmarketing; Risk Factors | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2003 |
Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.
Topics: Bone and Bones; Bone Resorption; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis | 2005 |
Newer drug treatments: their effects on fracture prevention.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Denosumab; Diphosphonates; Fractures, Bone; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thiophenes; Zoledronic Acid | 2005 |
Once-monthly ibandronate.
Topics: Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Maximum Tolerated Dose; Osteoporosis; Randomized Controlled Trials as Topic | 2005 |
Beyond daily dosing: clinical experience.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase II as Topic; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Ibandronic Acid; Osteoporosis; Treatment Outcome | 2006 |
Ibandronate: pharmacology and preclinical studies.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Ibandronic Acid; Osteoporosis; Ovariectomy | 2006 |
Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Interactions; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Neoplasms; Osteoporosis | 2006 |
Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; MEDLINE; Osteoporosis; Periodicals as Topic; Retrospective Studies | 2006 |
Effects of ibandronate on bone quality: preclinical studies.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Haplorhini; Ibandronic Acid; Osteoporosis; Rats | 2007 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
[Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Europe; Female; Humans; Ibandronic Acid; Injections, Intravenous; Japan; Osteoporosis; Patient Compliance; Randomized Controlled Trials as Topic; United States | 2007 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
[Ibandronate].
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; Osteoporosis | 2006 |
Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis; Postmenopause | 2007 |
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Drug Design; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Proportional Hazards Models; Time Factors | 2007 |
[New bone density conservation agents for osteoporosis under research and development: Ibandronate].
Topics: Administration, Oral; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Drug Design; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Research; Spinal Fractures | 2007 |
28 trial(s) available for ibandronic acid and Age-Related Osteoporosis
| Article | Year |
|---|---|
Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis | 2018 |
Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Male; Osteoporosis; Patient Compliance; Prospective Studies; Treatment Outcome | 2019 |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Japan; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Risedronic Acid; Spinal Fractures; Time Factors; Treatment Outcome | 2013 |
The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
Topics: Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Hemophilia A; Hemophilia B; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors | 2013 |
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; RANK Ligand | 2013 |
Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
Topics: Absorptiometry, Photon; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Biopsy; Bone Density; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Femur Neck; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis | 2014 |
The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties.
Topics: Administration, Oral; Area Under Curve; Asian People; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis; Peptides | 2016 |
Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Topics: Adaptor Proteins, Signal Transducing; Adult; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Bone Remodeling; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Finite Element Analysis; Genetic Markers; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis | 2015 |
Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures | 2015 |
Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Ibandronic Acid; Kidney Function Tests; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Risedronic Acid; Spinal Fractures; Vitamin D | 2016 |
Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Diphosphonates; Female; Femoral Neck Fractures; Femur Neck; Humans; Ibandronic Acid; Japan; Male; Middle Aged; Osteoporosis; Risedronic Acid; Spinal Fractures; Spine | 2017 |
Efficacy and safety of monthly ibandronate in men with low bone density.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Humans; Ibandronic Acid; Intention to Treat Analysis; Male; Middle Aged; Osteoporosis; Peptides; Treatment Outcome | 2010 |
Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Lupus Erythematosus, Systemic; Middle Aged; Osteoporosis; Prednisolone; Tomography Scanners, X-Ray Computed | 2010 |
Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Crohn Disease; Delayed-Action Preparations; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ibandronic Acid; Incidence; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Prevalence; Sodium Fluoride; Spinal Fractures; Treatment Outcome; Young Adult | 2011 |
Effect of monthly ibandronate on hip structural geometry in men with low bone density.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Femur; Femur Neck; Follow-Up Studies; Hip Joint; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Treatment Outcome | 2012 |
Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Glucocorticoids; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Postmenopause; Rheumatic Diseases; Treatment Outcome | 2012 |
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.
Topics: Administration, Intravenous; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcitriol; Calcium, Dietary; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Kidney Transplantation; Male; Maximum Tolerated Dose; Middle Aged; Osteoporosis; Vitamins | 2012 |
Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation.
Topics: Bone Density; Bone Resorption; Calcium; Diphosphonates; Femur; Humans; Ibandronic Acid; Liver Transplantation; Lumbar Vertebrae; Osteoporosis; Postoperative Complications; Vitamin D | 2002 |
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.
Topics: Bone Density; Crohn Disease; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Sodium Fluoride | 2003 |
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
Topics: Aged; Back Pain; Bone Density; Calcaneus; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prospective Studies; Spinal Fractures | 2003 |
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
Topics: Aged; Back Pain; Body Height; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Spinal Fractures | 2003 |
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density; Diphosphonates; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Pilot Projects; Spine | 2003 |
Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
Topics: Aged; Bone Density; Bone Remodeling; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis; Placebos | 2004 |
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
Topics: Aged; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis; Placebos; Postmenopause | 2004 |
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Resorption; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Ibandronic Acid; Middle Aged; North America; Osteoporosis; Postmenopause; Spinal Fractures; White People | 2005 |
Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis; Prospective Studies; Time Factors; Treatment Outcome | 2008 |
Effect of ibandronate on bone loss and renal function after kidney transplantation.
Topics: Adult; Body Height; Bone Density; Diphosphonates; Female; Graft Rejection; Humans; Ibandronic Acid; Kidney; Kidney Transplantation; Male; Middle Aged; Osteoporosis; Spinal Diseases; Transplantation, Homologous; Treatment Outcome | 2001 |
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.
Topics: Alendronate; Analysis of Variance; Bone Resorption; Cartilage; Collagen Type I; Collagen Type II; Diphosphonates; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis | 2002 |
71 other study(ies) available for ibandronic acid and Age-Related Osteoporosis
| Article | Year |
|---|---|
Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae.
Topics: Animals; Apatites; Bone Density; Bone Diseases, Metabolic; Elastic Modulus; Endocrine System Diseases; Estrogens; Ibandronic Acid; Osteoporosis; Rats; Spine | 2022 |
Combination treatment with ibandronate and eldecalcitol prevents osteoporotic bone loss and deterioration of bone quality characterized by nano-arrangement of the collagen/apatite in an ovariectomized aged rat model.
Topics: Animals; Apatites; Bone Density; Bone Diseases, Metabolic; Collagen; Estrogens; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Vitamin D | 2022 |
Association Between Antiosteoporotic Drugs and Risk of Acute Kidney Injury: A Cross-Sectional Study Using Disproportional Analysis and a Pharmacovigilance Database.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Alendronate; Cross-Sectional Studies; Databases, Factual; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Pharmaceutical Preparations; Pharmacovigilance; Selective Estrogen Receptor Modulators; Teriparatide | 2022 |
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2022 |
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Taiwan; Teriparatide; Zoledronic Acid | 2022 |
Real-world effectiveness of osteoporosis treatments in Germany.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference.
Topics: Alendronate; Bone Density Conservation Agents; Humans; Ibandronic Acid; Osteoporosis; Taiwan; Urbanization | 2023 |
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic Acid; Osteoporosis; Pamidronate; Pharmaceutical Preparations; Risedronic Acid | 2023 |
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2023 |
Micro-CT imaging analysis for the effects of ibandronate and eldecalcitol on secondary osteoporosis and arthritis in adjuvant-induced arthritis rats.
Topics: Animals; Arthritis, Experimental; Biopsy; Disease Models, Animal; Ibandronic Acid; Imaging, Three-Dimensional; Joints; Osteoporosis; Phenotype; Proteoglycans; Rats; Vitamin D; X-Ray Microtomography | 2019 |
Effects of monthly intravenous ibandronate on bone mineral density and microstructure in patients with primary osteoporosis after teriparatide treatment: The MONUMENT study.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Humans; Ibandronic Acid; Osteoporosis; Teriparatide | 2021 |
Effect of lumbar spinal stenosis on bone mineral density in osteoporosis patients treated with ibandronate.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis; Spinal Stenosis; Treatment Outcome | 2021 |
Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
Topics: Absorptiometry, Photon; Administration, Intravenous; Administration, Oral; Aged; Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Female; Hip; Humans; Hydroxycholecalciferols; Ibandronic Acid; Osteoporosis; Postmenopause; Tartrate-Resistant Acid Phosphatase | 2017 |
Bad Breaks.
Topics: Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Female; Fractures, Bone; Humans; Hypocalcemia; Ibandronic Acid; Middle Aged; Osteoporosis; Pubic Bone; Sacrum; Vitamin D Deficiency | 2018 |
Erythema multiforme caused by ibandronate sodium: A rare case report.
Topics: Bone Density Conservation Agents; Drug Eruptions; Erythema Multiforme; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis | 2019 |
Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report.
Topics: Adrenal Cortex Hormones; Chemical and Drug Induced Liver Injury; Contraindications; Diphosphonates; Female; Humans; Hydroxychloroquine; Ibandronic Acid; Lupus Erythematosus, Systemic; Middle Aged; Osteoporosis; Steroids; Treatment Outcome; Withholding Treatment | 2013 |
[Transient QT-interval prolongation and T wave inversion: diagnostic difficulties].
Topics: Aged; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Electrocardiography; Female; Humans; Ibandronic Acid; Long QT Syndrome; Osteoporosis | 2013 |
[Not Available].
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Long QT Syndrome; Osteoporosis | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Thiophenes | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Evaluation of parathyroid levels and bone densitometry after cinacalcet treatment in severe primary hyperparathyroidism.
Topics: Alkaline Phosphatase; Bone Density; Calcium; Cinacalcet; Diphosphonates; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Ibandronic Acid; Naphthalenes; Osteoporosis; Parathyroid Hormone; Phosphates; Vitamin D | 2013 |
Ventricular tachycardia-based long QT without hypocalcaemia after use of ibandronic acid.
Topics: Bone Density Conservation Agents; Diphosphonates; Echocardiography; Electrocardiography; Female; Heart Ventricles; Humans; Hypocalcemia; Ibandronic Acid; Middle Aged; Osteoporosis; Recovery of Function; Tachycardia, Ventricular; Tricuspid Valve Insufficiency; Withholding Treatment | 2013 |
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Male; Markov Chains; Osteoporosis; Osteoporotic Fractures; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2014 |
The time-dependent effect of ibandronate on bone graft remodeling in an ovariectomized rat spinal arthrodesis model.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Transplantation; Diphosphonates; Female; Femur; Ibandronic Acid; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Spinal Fusion; Time Factors | 2014 |
Exacerbation of myasthenia gravis by alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Humans; Ibandronic Acid; Male; Myasthenia Gravis; Osteoporosis; Young Adult | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; United States | 2015 |
Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Ibandronic Acid; Kidney Transplantation; Lumbar Vertebrae; Male; Osteoporosis; Retrospective Studies; Time Factors; Transplant Recipients; Treatment Outcome | 2016 |
Atypical femoral fracture following zoledronic acid treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Femoral Fractures; Fracture Fixation; Humans; Ibandronic Acid; Imidazoles; Magnetic Resonance Imaging; Osteoporosis; Treatment Outcome; Withholding Treatment; Zoledronic Acid | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Effects of combined treatment with ibandronate and pulsed electromagnetic field on ovariectomy-induced osteoporosis in rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Combined Modality Therapy; Diphosphonates; Electromagnetic Fields; Female; Femur; Gene Expression Regulation; Ibandronic Acid; Magnetic Field Therapy; Osteoporosis; Osteoprotegerin; Ovariectomy; RANK Ligand; Rats; RNA, Messenger; Spine; Tartrate-Resistant Acid Phosphatase; X-Ray Microtomography | 2017 |
Ibandronate in the Treatment of Pediatric Osteoporosis.
Topics: Adolescent; Bone Density; Child; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Osteoporosis | 2016 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; Diphosphonates; Drug Utilization; Ergocalciferols; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Risedronic Acid | 2016 |
[Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Osteoporosis; Zoledronic Acid | 2008 |
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Hip Fractures; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies | 2009 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Risk Factors | 2009 |
Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Etidronic Acid; Female; Humans; Ibandronic Acid; Longitudinal Studies; Male; Middle Aged; Osteoporosis; Patient Compliance; Retrospective Studies; Risedronic Acid | 2009 |
Pricey osteoporosis remedy doesn't beat older drugs.
Topics: Advertising; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Dietary; Diphosphonates; Drug Costs; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Vitamin D | 2009 |
Safety and antisorptive power of Ibandronate applied in the real-life setting.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Thailand; Treatment Outcome | 2009 |
[Anti-fracture efficacy of intravenous ibandronate: how to translate epidemiological studies into daily clinical practice].
Topics: Bone Density Conservation Agents; Clinical Medicine; Diphosphonates; Fractures, Spontaneous; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis | 2009 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Liver Cirrhosis, Biliary; Male; Middle Aged; Osteoporosis; Pamidronate; Retrospective Studies; Zoledronic Acid | 2011 |
Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.
Topics: Aged; Alendronate; Aortic Valve Stenosis; Bone Density Conservation Agents; Calcinosis; Comorbidity; Diphosphonates; Disease Progression; Female; Hemodynamics; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Pilot Projects; Retrospective Studies | 2010 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diphosphonates; Drug Costs; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Insurance Claim Review; Longitudinal Studies; Male; Managed Care Programs; Medication Adherence; Middle Aged; Osteoporosis; Regression Analysis; Retrospective Studies; Risedronic Acid; United States | 2011 |
Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Femur Neck; Glucocorticoids; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis; Rabbits; Weight-Bearing | 2012 |
Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.
Topics: Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcitriol; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Ibandronic Acid; Liver Transplantation; Male; Middle Aged; Osteoporosis; Parathyroid Hormone; Risk | 2012 |
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Logistic Models; Male; Medicare; Medication Adherence; Osteoporosis; Patient Compliance; United States; Zoledronic Acid | 2012 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid | 2013 |
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Cohort Studies; Debridement; Diphosphonates; Female; Follow-Up Studies; Glucocorticoids; Humans; Ibandronic Acid; Male; Middle Aged; Osteolysis; Osteoporosis; Osteosclerosis; Retrospective Studies; Tooth Extraction; Treatment Outcome; Wound Healing | 2012 |
Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.
Topics: Absorptiometry, Photon; Administration, Oral; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chi-Square Distribution; Cholecalciferol; Creatinine; Dietary Supplements; Diphosphonates; Drug Administration Schedule; Femur Neck; Fractures, Bone; Germany; Humans; Ibandronic Acid; Liver Transplantation; Lumbar Vertebrae; Osteoporosis; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
Topics: Bone Density Conservation Agents; Cost Sharing; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Markov Chains; Middle Aged; Osteoporosis; Reimbursement Mechanisms; Risedronic Acid | 2012 |
Review of ibandronate in the treatment of osteoporosis.
Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic | 2003 |
Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey.
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Densitometry; Diphosphonates; DNA; Dose-Response Relationship, Drug; Female; Ibandronic Acid; Linear Models; Lumbar Vertebrae; Lumbosacral Region; Macaca fascicularis; Osteoporosis; Ovariectomy; Ovary; Spine; Tensile Strength; Time Factors; Tomography, X-Ray Computed | 2004 |
Longer-lasting osteoporosis drugs sought.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Zoledronic Acid | 2005 |
The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Durapatite; Female; Femur; Ibandronic Acid; Osseointegration; Osteoporosis; Ovariectomy; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Titanium | 2005 |
A new option for osteoporosis.
Topics: Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis | 2005 |
First once-a-month osteoporosis pill approved.
Topics: Diphosphonates; Drug Administration Schedule; Drug Approval; Female; Humans; Ibandronic Acid; Osteoporosis | 2005 |
A bright future for osteoporosis treatment.
Topics: Adrenergic beta-Antagonists; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Lithium Compounds; Osteogenesis; Osteoporosis; Receptor, Cannabinoid, CB1; Risedronic Acid | 2005 |
Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Marrow; Bone Resorption; Calcium, Dietary; Dietary Supplements; Diphosphonates; Edema; Female; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Pain; Pain Measurement; Quality of Life; Syndrome; Treatment Outcome; Vitamin D | 2005 |
[DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Minimally Invasive Surgical Procedures; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Recombinant Proteins; Spinal Fractures; Teriparatide; Thiophenes | 2006 |
Intravenous ibandronate in the treatment of osteoporosis: profile report.
Topics: Bone Density; Diphosphonates; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis | 2006 |
Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Glucocorticoids; Ibandronic Acid; Lumbar Vertebrae; Osteoporosis; Swine; Swine, Miniature | 2007 |
Prevention and treatment of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Glucocorticoids; Humans; Ibandronic Acid; Male; Osteoporosis; Parathyroid Hormone; Patient Compliance; Practice Guidelines as Topic; Quality of Health Care; Rheumatic Diseases; Time Factors; Vitamin D; Vitamin K | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis; Osteoporosis; Risedronic Acid | 2007 |
Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Combinations; Drug Costs; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Models, Economic; Netherlands; Osteoporosis; Patient Compliance; Patient Simulation; Quality-Adjusted Life Years; United Kingdom | 2008 |
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Cost-Benefit Analysis; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Inflammatory Bowel Diseases; Male; Markov Chains; Models, Economic; Osteoporosis; Quality-Adjusted Life Years; Sodium Fluoride | 2008 |
A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs.
Topics: Animals; Bone and Bones; Bone Resorption; Calcitriol; Diphosphonates; Dogs; Female; Ibandronic Acid; Models, Biological; Osteoporosis; Ovariectomy; Parathyroid Hormone | 1993 |
Ibandronic acid. BM 210955, RPR 102289A, methylpentylaminopropylidene, Bondronat Bonviva.
Topics: Animals; Diphosphonates; Dogs; Drug Interactions; Drugs, Investigational; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal | 1999 |
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Muscle, Smooth, Vascular; Osteoporosis; Rats; Rats, Sprague-Dawley; Vitamin D; Warfarin | 2001 |
Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats.
Topics: Aging; Animals; Bone Density; Diphosphonates; Dose-Response Relationship, Drug; Female; Femur; Ibandronic Acid; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Tibia | 2002 |